Protease-activated receptor-2 regulates glial scar formation via JNK signaling
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
30628825
DOI
10.33549/physiolres.933908
PII: 933908
Knihovny.cz E-zdroje
- MeSH
- anisomycin farmakologie MeSH
- anthraceny farmakologie MeSH
- jizva metabolismus patologie prevence a kontrola MeSH
- krysa rodu Rattus MeSH
- MAP kinasový signální systém účinky léků fyziologie MeSH
- poranění míchy metabolismus patologie MeSH
- potkani Sprague-Dawley MeSH
- receptor PAR-2 antagonisté a inhibitory biosyntéza MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- anisomycin MeSH
- anthraceny MeSH
- pyrazolanthrone MeSH Prohlížeč
- receptor PAR-2 MeSH
The study aimed to determine the effects of protease-activated receptor-2 (PAR-2) on glial scar formation after spinal cord injury (SCI) in Sprague-Dawley (SD) rats and the underlying mechanisms. Rivlin and Tator's acute extradural clip compression injury (CCI) model of severe SCI was established in this study. Animals were divided into four groups: 1) sham group (laminectomy only); 2) model group, treated with normal saline; 3) PAR-2 inhibitor group; 4) PAR-2 activator group. Enhanced GFAP and vimentin expression were the markers of glial scar formation. To determine whether JNK was involved in the effects of PAR-2 on GFAP and vimentin expression, we administered anisomycin (a JNK activator) in the presence of PAR-2 inhibitor and SP600125 (a JNK inhibitor) in the presence of PAR-2 activator. At 1, 7, 14 and 28 day after SCI, Basso, Beattie, and Bresnahan (BBB) locomotor score test was used to assess the locomotor functional recovery; immunofluorescence and western blot analysis were used to assess the expression level of GFAP, vimentin and p-JNK. Double immunofluorescence staining with GFAP and tubulin beta was used to assess the glial scar formation and the remaining neurons. Results suggested that PAR-2 is involved in glial scar formation and reduces neurons residues which can cause a further worsening in the functional outcomes after SCI via JNK signaling. Therefore, it may be effective to target PAR-2 in the treatment of SCI.
Citace poskytuje Crossref.org
PAR2: The Cornerstone of Pancreatic Diseases